Inmune Bio: regulation fd disclosure

Form 8-K filed Oct 21, 2026 · items 7.01, 8.01

FDA decisionsInitial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization

What the filing says

INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization

Read the filing on SEC EDGAR →

What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

Inmune Bio’s other material 8-Ks

Oct 29, 2026 — FDA decisions INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Privat

Other recent fda decisions

Biovie Nov 6, 2026
Acrivon Therapeutics Nov 6, 2026
Entera Bio Nov 6, 2026
Precision Biosciences Nov 5, 2026
Sintx Technologies Nov 5, 2026
Microbot Medical Nov 5, 2026
Bioxytran Nov 5, 2026
Palvella Therapeutics Nov 5, 2026
ANI Pharmaceuticals Nov 5, 2026
Teleflex Nov 5, 2026

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.